The Food and Drug Administration is launching a new hepatitis list serve. This new e-mail list will provide updates on safety and regulatory issues related to hepatitis B and C products as they become available (rather than on a regularly scheduled basis).

The e-mail list is intended to give patients, industry, academia, government agencies, and other interested parties, one source for FDA hepatitis B and C related information on a variety of topics, including:

• product approvals
• significant labeling changes
• safety warnings
• notices of upcoming public meetings
• proposed regulatory guidances and opportunity to comment

You can subscribe to the new hepatitis e-mail list by simply clicking the link below:

http://service.govdelivery.com/service/subscribe.html?code=USFDA_99

or pasting it into your browser.

You will get an e-mail acknowledgment shortly after signing up.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration